Accepted Manuscript

Chemotherapy and tyrosine-kinase inhibitors for medullary thryoid cancer


Julien Hadoux, MD, Martin Schlumberger, MD.

PII: S1521-690X(17)30037-4


DOI: 10.1016/j.beem.2017.04.009

Reference: YBEEM 1150

To appear in: Best Practice & Research Clinical Endocrinology & Metabolism



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

1	Manuscript Title:
2	Chemotherapy and tyrosine-kinase inhibitors for medullary thryoid cancer.
3	
4	Authors:
5	Julien Hadoux MD, Martin Schlumberger MD.
6	
7	Affiliations:
8	JH and MS: Department of Nuclear Medicine and Endocrine Oncology, Gustave
9	Roussy and Université Paris Saclay, 114 rue Edouard Vaillant, 94800 Villejuif,
10 11	France.
12	Corresponding author: Pr Martin Schlumberger,
13	Department of Nuclear Medicine and Endocrine Oncology
14	Gustave Roussy
15	114 rue Edouard Vaillant
16	94805 Villejuif Cedex. France
17	Phone: +33(0)142116095
18	Fax: +33(0)142116363
19	martin.schlumberger@gustaveroussy.fr
20	
21	Word counts: Abstract: 173 words. Text: 4547 words
22	Number of figures and tables: 2 tables and 1 figure
23	Keywords: medullary thyroid cancer, RET, tyrosine kinase inhibitors, vandetanib
24	cabozantinib, chemotherapy.

Download English Version:

https://daneshyari.com/en/article/5586628

Download Persian Version:

https://daneshyari.com/article/5586628

<u>Daneshyari.com</u>